Semax vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Semax | Retatrutide |
|---|---|---|
| Mechanism | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May cause mild irritability or hair shedding in some users. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |